Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VTYX |
---|---|---|
09:32 ET | 3740 | 3.345 |
09:34 ET | 1592 | 3.34 |
09:36 ET | 750 | 3.335 |
09:38 ET | 9537 | 3.326 |
09:39 ET | 9103 | 3.36 |
09:41 ET | 1918 | 3.3212 |
09:43 ET | 8649 | 3.35 |
09:45 ET | 400 | 3.35 |
09:48 ET | 3529 | 3.36 |
09:50 ET | 600 | 3.35 |
09:52 ET | 1541 | 3.36 |
09:54 ET | 360 | 3.36 |
09:56 ET | 728 | 3.355 |
09:57 ET | 729 | 3.3512 |
09:59 ET | 4758 | 3.3 |
10:01 ET | 6247 | 3.27 |
10:03 ET | 3047 | 3.2501 |
10:08 ET | 1487 | 3.2588 |
10:10 ET | 2850 | 3.26 |
10:12 ET | 100 | 3.245 |
10:14 ET | 7394 | 3.21 |
10:15 ET | 4210 | 3.2 |
10:17 ET | 4916 | 3.21 |
10:19 ET | 5592 | 3.25 |
10:21 ET | 4365 | 3.24 |
10:24 ET | 1037 | 3.23 |
10:26 ET | 500 | 3.23 |
10:28 ET | 500 | 3.2331 |
10:30 ET | 615 | 3.235 |
10:32 ET | 1241 | 3.234 |
10:33 ET | 4677 | 3.25 |
10:35 ET | 4765 | 3.24 |
10:37 ET | 2800 | 3.24 |
10:39 ET | 300 | 3.23 |
10:42 ET | 506 | 3.235 |
10:44 ET | 452 | 3.23 |
10:46 ET | 3006 | 3.25 |
10:48 ET | 3060 | 3.255 |
10:50 ET | 2330 | 3.2588 |
10:51 ET | 923 | 3.265 |
10:53 ET | 1800 | 3.26 |
10:55 ET | 2089 | 3.245 |
10:57 ET | 1608 | 3.23 |
11:00 ET | 100 | 3.235 |
11:02 ET | 5346 | 3.24 |
11:04 ET | 1794 | 3.23 |
11:06 ET | 400 | 3.225 |
11:08 ET | 3242 | 3.2188 |
11:09 ET | 3084 | 3.195 |
11:11 ET | 518 | 3.195 |
11:13 ET | 404 | 3.1912 |
11:15 ET | 6195 | 3.215 |
11:18 ET | 412 | 3.215 |
11:20 ET | 1787 | 3.215 |
11:22 ET | 892 | 3.21 |
11:24 ET | 1273 | 3.21 |
11:26 ET | 862 | 3.22 |
11:27 ET | 400 | 3.225 |
11:29 ET | 300 | 3.22 |
11:31 ET | 100 | 3.215 |
11:36 ET | 2330 | 3.2 |
11:38 ET | 3669 | 3.205 |
11:40 ET | 5742 | 3.2099 |
11:42 ET | 2279 | 3.2112 |
11:44 ET | 1600 | 3.22 |
11:45 ET | 400 | 3.22 |
11:47 ET | 13928 | 3.185 |
11:49 ET | 5426 | 3.18 |
11:51 ET | 3100 | 3.1799 |
11:54 ET | 4596 | 3.175 |
11:56 ET | 10909 | 3.18 |
11:58 ET | 3162 | 3.21 |
12:00 ET | 100 | 3.205 |
12:02 ET | 2135 | 3.2025 |
12:03 ET | 2735 | 3.21 |
12:05 ET | 700 | 3.24 |
12:07 ET | 8377 | 3.244 |
12:09 ET | 500 | 3.24 |
12:12 ET | 3591 | 3.24 |
12:14 ET | 5163 | 3.25 |
12:16 ET | 400 | 3.24 |
12:18 ET | 2657 | 3.21 |
12:20 ET | 1000 | 3.21 |
12:21 ET | 4444 | 3.19 |
12:23 ET | 2500 | 3.2 |
12:25 ET | 200 | 3.19 |
12:27 ET | 900 | 3.205 |
12:30 ET | 1000 | 3.2 |
12:32 ET | 3711 | 3.2 |
12:34 ET | 1512 | 3.2088 |
12:36 ET | 3522 | 3.21 |
12:38 ET | 870 | 3.22 |
12:39 ET | 1013 | 3.22 |
12:41 ET | 1297 | 3.2112 |
12:43 ET | 1600 | 3.23 |
12:45 ET | 3820 | 3.24 |
12:48 ET | 516 | 3.25 |
12:52 ET | 238 | 3.25 |
12:54 ET | 1480 | 3.245 |
12:56 ET | 2983 | 3.24 |
12:57 ET | 580 | 3.24 |
01:01 ET | 1152 | 3.23 |
01:03 ET | 4926 | 3.255 |
01:06 ET | 100 | 3.255 |
01:12 ET | 1129 | 3.265 |
01:14 ET | 500 | 3.2688 |
01:15 ET | 7636 | 3.2511 |
01:17 ET | 1580 | 3.24 |
01:21 ET | 2946 | 3.22 |
01:24 ET | 1228 | 3.2188 |
01:26 ET | 6140 | 3.2099 |
01:28 ET | 6634 | 3.225 |
01:30 ET | 200 | 3.215 |
01:32 ET | 638 | 3.22 |
01:33 ET | 3825 | 3.25 |
01:35 ET | 800 | 3.245 |
01:37 ET | 13603 | 3.2388 |
01:39 ET | 3007 | 3.24 |
01:42 ET | 940 | 3.2495 |
01:46 ET | 400 | 3.24 |
01:48 ET | 845 | 3.2432 |
01:50 ET | 11278 | 3.2588 |
01:51 ET | 2789 | 3.25 |
01:53 ET | 2564 | 3.24 |
01:55 ET | 1227 | 3.25 |
01:57 ET | 3873 | 3.245 |
02:00 ET | 1871 | 3.22 |
02:02 ET | 814 | 3.22 |
02:04 ET | 2312 | 3.22 |
02:06 ET | 200 | 3.21 |
02:08 ET | 7118 | 3.2001 |
02:09 ET | 500 | 3.198 |
02:11 ET | 400 | 3.195 |
02:13 ET | 7690 | 3.1997 |
02:15 ET | 1111 | 3.1988 |
02:18 ET | 740 | 3.195 |
02:20 ET | 733 | 3.1988 |
02:22 ET | 14112 | 3.1901 |
02:24 ET | 3500 | 3.1999 |
02:26 ET | 3862 | 3.19 |
02:27 ET | 2420 | 3.1888 |
02:29 ET | 3222 | 3.18 |
02:31 ET | 3164 | 3.17 |
02:33 ET | 4744 | 3.17 |
02:36 ET | 7070 | 3.17 |
02:38 ET | 3987 | 3.1699 |
02:40 ET | 35035 | 3.17 |
02:42 ET | 19856 | 3.18 |
02:44 ET | 10099 | 3.1878 |
02:45 ET | 1072 | 3.19 |
02:47 ET | 634 | 3.185 |
02:49 ET | 2663 | 3.185 |
02:51 ET | 200 | 3.185 |
02:54 ET | 7719 | 3.18 |
02:56 ET | 700 | 3.185 |
02:58 ET | 700 | 3.18 |
03:00 ET | 1429 | 3.1899 |
03:02 ET | 700 | 3.185 |
03:03 ET | 6034 | 3.19 |
03:05 ET | 210 | 3.195 |
03:07 ET | 575 | 3.195 |
03:09 ET | 12582 | 3.19 |
03:12 ET | 704 | 3.195 |
03:14 ET | 2552 | 3.195 |
03:16 ET | 200 | 3.195 |
03:18 ET | 600 | 3.19 |
03:20 ET | 900 | 3.1999 |
03:21 ET | 2665 | 3.195 |
03:23 ET | 4514 | 3.19 |
03:25 ET | 8413 | 3.195 |
03:27 ET | 1600 | 3.19 |
03:30 ET | 1000 | 3.1999 |
03:32 ET | 6673 | 3.195 |
03:34 ET | 5600 | 3.19 |
03:36 ET | 3106 | 3.195 |
03:38 ET | 5989 | 3.185 |
03:39 ET | 40087 | 3.18 |
03:41 ET | 33834 | 3.135 |
03:43 ET | 16410 | 3.15 |
03:45 ET | 7272 | 3.16 |
03:48 ET | 2406 | 3.16 |
03:50 ET | 13429 | 3.15 |
03:52 ET | 5083 | 3.15 |
03:54 ET | 3219 | 3.16 |
03:56 ET | 20185 | 3.18 |
03:57 ET | 62785 | 3.2 |
03:59 ET | 167091 | 3.2 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Ventyx Biosciences Inc | 229.8M | -1.0x | --- |
Rezolute Inc | 229.6M | -4.7x | --- |
Aldeyra Therapeutics Inc | 229.3M | -7.4x | --- |
ATAI Life Sciences NV | 232.7M | -5.5x | --- |
Acrivon Therapeutics Inc | 223.9M | -2.6x | --- |
Pyxis Oncology Inc | 223.8M | -2.8x | --- |
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet need. The Company’s pipeline includes VTX002 (S1P1R Modulator), VTX958 (TYK2 Inhibitor), and VTX2735 and VTX3232 (NLRP3 Inhibitor Portfolio). VTX002 is a sphingosine 1 phosphate receptor (S1P1R) modulator in Phase II development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is an oral, selective clinical-stage inhibitor of tyrosine kinase type 2 (TYK2), an intracellular signaling kinase in the Janus kinase (JAK) family that regulates chronic inflammation in immune-mediated diseases. Its third product candidate, VTX2735, is a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor. In addition to VTX2735, it is also developing VTX3232, its lead CNS-penetrant NLRP3 inhibitor in Phase 1 development.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $229.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.24 |
Book Value | $4.12 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.